Abstract Number: 0328 • ACR Convergence 2023
From Patient Needs to Platform Design: Using Patient Preference to Guide the Development of a Post-Viral Fibromyalgia Management App
Background/Purpose: Post-viral fibromyalgia is a chronic condition that can develop in individuals following a viral infection, such as COVID-19. Recent studies have shown that approximately…Abstract Number: 1827 • ACR Convergence 2023
Revolutionizing Fibromyalgia Treatment: Exploring the Efficacy of a New FDA Cleared Photoceutical Device
Background/Purpose: Fibromyalgia syndrome effects 2-8% of the general population and is characterized by specific tender points. FM annual economic impact $12-$14 billion.Current treatments are only…Abstract Number: 0404 • ACR Convergence 2023
Persistent Pain and Its Predictors After Start of Anti-TNF Therapy in Rheumatoid Arthritis – Is Line of Treatment Linked to Different Pain Patterns?
Background/Purpose: Persisting pain with or without inflammation control is a common and debilitating symptom in rheumatoid arthritis (RA). Concerns have been raised that patients with…Abstract Number: 1828 • ACR Convergence 2023
Positive Screening for Fibromyalgia or Depression on Validated MDHAQ Indices Is Seen in 56-71% of Rheumatoid Arthritis Patients with High DAS28 or CDAI, 40-47% with Moderate, 2-42% with Low, and 0-21% with DAS28 or CDAI Remission
Background/Purpose: DAS28 (disease activity score 28) and CDAI (clinical disease activity index) are prominent indices to assess patients with rheumatoid arthritis (RA) quantitatively, for which…Abstract Number: 0454 • ACR Convergence 2023
Rheumatoid Arthritis Disease Activity Indices Assess More Than Inflammation: 29%-36% of Patients with Moderate or High DAS28–ESR or CDAI Have 0 or 1 Swollen Joints, but Positive Screens on MDHAQ FAST4 (fibromyalgia Assessment Screening Tool) And/or MDS2 (MDHAQ Depression Screen) Indices
Background/Purpose: Rheumatoid arthritis (RA) therapy is recommended to be intensified according to treat-to-target if DAS28 (disease activity score 28) or CDAI (clinical disease activity index)…Abstract Number: 1829 • ACR Convergence 2023
Blood-derived Extracellular Vesicles as Potential Diagnostic Biomarker in Fibromyalgia Syndrome
Background/Purpose: The Fibromyalgia syndrome (FMS) is a global chronic pain condition, which affects approximately 2–6% of the population. The underlying mechanism of FMS is unclear…Abstract Number: 0483 • ACR Convergence 2023
The Influence of “Fibromyalgia-ness” on Treatment Response Amongst Patients with Psoriatic Arthritis (PsA). Results from the British Society for Rheumatology Psoriatic Arthritis Register (BSR‐PsA)
Background/Purpose: Co-morbid fibromyalgia has been shown to be an important influence on non-response in patients with some inflammatory arthritides. Around 1 in 5 patients with…Abstract Number: 1831 • ACR Convergence 2023
Effect of the COVID-19 Pandemic on Health Status of Fibromyalgia
Background/Purpose: Fibromyalgia (FM) symptoms fluctuate, with exacerbation commonly associated with stressors. The COVID-19 pandemic was a cause of prolonged stress due to factors such as…Abstract Number: 1189 • ACR Convergence 2023
Evaluating Neuropathic and Nociplastic Pain in Patients with Hip and Knee Osteoarthritis
Background/Purpose: Chronic pain in patients with hip and knee osteoarthritis (OA) has been classically attributed to nociceptive pain pathways. Emerging evidence has demonstrated influence from…Abstract Number: 1832 • ACR Convergence 2023
Prevalence of Musculoskeletal Manifestations in Post-acute COVID 19 Patients and Their Quality of Life at Kenyatta National Hospital
Background/Purpose: Since its discovery in Wuhan, China, severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) has ravaged the globe on an unprecedented scale. While…Abstract Number: 1290 • ACR Convergence 2023
Development of a Genetic Risk Score for Pain in Rheumatoid Arthritis
Background/Purpose: Pain in rheumatoid arthritis (RA) is multifactorial and involves processes beyond inflammation such as peripheral and central pain processing. Several genes have been associated…Abstract Number: 1833 • ACR Convergence 2023
Development of a Polygenic Risk Model for Therapeutic Response to Bedtime Sublingual Cyclobenzaprine (TNX-102 SL*) in Fibromyalgia Based on Polygenic Single Nucleotide Polymorphism (SNP)-Count Scores
Background/Purpose: Fibromyalgia (FM) is characterized by widespread pain, non-restorative sleep, fatigue, and cognitive dysfunction. TNX-102 SL is a sublingual cyclobenzaprine tablet designed for daily use…Abstract Number: 1421 • ACR Convergence 2023
Domains Impacting Minimal Disease Activity Non-Achievement in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors Receiving Guselkumab (COSMOS)
Background/Purpose: Sustained minimal disease activity (MDA) is achieved by a minority of patients (pts) receiving biologics for psoriatic arthritis (PsA). Pt-reported MDA domains are less…Abstract Number: 1834 • ACR Convergence 2023
Evaluation of Fibromyalgia, Clinical/Serologic Activity, and Patient Reported Outcomes in a Racially/Ethnically Diverse SLE Patient Cohort
Background/Purpose: SLE patients have a higher prevalence of fibromyalgia (FM) than the general population. FM symptoms, such as nociplastic pain and fatigue, are known to…Abstract Number: 1575 • ACR Convergence 2023
Takayasu Arteritis Is Associated with Worse Fatigue Than Healthy Controls Which Persists over Time – A Longitudinal Cohort Study
Background/Purpose: Few studies have assessed patient-reported outcome measures in Takayasu arteritis (TAK), a rare large vessel vasculitis. We prospectively analysed fatigue and fibromyalgia in TAK…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 25
- Next Page »